Q-omics provides the consensus-scored EDA profile across patient tissues and cancer cell-line models. EDA expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, EDA is differentially expressed in 12, with the highest sampling consensus in LUAD. Additionally, EDA RNA expression shows 17,257 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KIRC, LUAD, and THYM as cancer lineages where EDA shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for EDA — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes EDA survival associations across molecular data types. EDA RNA expression shows survival associations in the most cancer types (24), followed by mutation status (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible EDA RNA expression–survival associations across cancer types. High EDA expression shows unfavorable associations in HNSC and ESCA, but favorable associations in KIRC, MESO, ACC and OV. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for EDA RNA expression.
This table summarizes EDA tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in LUAD for RNA.
This table ranks reproducible tumor–normal expression differences for EDA. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. EDA shows lower tumor expression in LUAD, BLCA, BRCA, THCA and LUSC and higher tumor expression in CHOL. The LUAD box plot shows higher EDA RNA expression in normal versus tumor tissue (log2 FC = −1.101, t-test p < 0.001).
This table shows molecular features associated with EDA in patient tissues and cancer cell lines. In patient samples, EDA shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, EDA RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in STOMACH and BONE.
